Targeting MET in NSCLC: Looking for a Needle in a Haystack

Overview

Journal Transl Lung Cancer Res

Date 2015 Mar 26

PMID 25806329

Citations 5

Authors

Lorenza Landi

Federico Cappuzzo

Affiliations

Soon will be listed here.

Citing Articles

Role of cytokines in combinatorial immunotherapeutics of non-small cell lung cancer through systems perspective.

Misra P, Singh S Cancer Med. 2019; 8(5):1976-1995.

PMID: 30997737 PMC: 6536974. DOI: 10.1002/cam4.2112.

Impact of a five-dimensional framework on R&D productivity at AstraZeneca.

Morgan P, Brown D, Lennard S, Anderton M, Barrett J, Eriksson U Nat Rev Drug Discov. 2018; 17(3):167-181.

PMID: 29348681 DOI: 10.1038/nrd.2017.244.

Na/K Pump and Beyond: Na/K-ATPase as a Modulator of Apoptosis and Autophagy.

Goncalves-de-Albuquerque C, Silva A, Silva C, Castro-Faria-Neto H, Burth P Molecules. 2017; 22(4).

PMID: 28430151 PMC: 6154632. DOI: 10.3390/molecules22040578.

Zr-Onartuzumab PET imaging of c-MET receptor dynamics.

Pool M, van Scheltinga A, Kol A, Giesen D, de Vries E, Lub-de Hooge M Eur J Nucl Med Mol Imaging. 2017; 44(8):1328-1336.

PMID: 28315949 PMC: 5486818. DOI: 10.1007/s00259-017-3672-x.

Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.

Dong X, Fernandez-Salas E, Li E, Wang S Neoplasia. 2016; 18(3):162-71.

PMID: 26992917 PMC: 4796802. DOI: 10.1016/j.neo.2016.02.001.

References

Cappuzzo F, Janne P, Skokan M, Finocchiaro G, Rossi E, Ligorio C . MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol. 2008; 20(2):298-304. PMC: 2733067. DOI: 10.1093/annonc/mdn635. View

Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L . Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol. 2009; 27(10):1667-74. PMC: 3341799. DOI: 10.1200/JCO.2008.19.1635. View

Spigel D, Ervin T, Ramlau R, Daniel D, Goldschmidt Jr J, Blumenschein Jr G . Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2013; 31(32):4105-14. PMC: 4878106. DOI: 10.1200/JCO.2012.47.4189. View

Engelman J, Janne P . Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. 2008; 14(10):2895-9. DOI: 10.1158/1078-0432.CCR-07-2248. View

Smolen G, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H . Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A. 2006; 103(7):2316-21. PMC: 1413705. DOI: 10.1073/pnas.0508776103. View